Cautious Optimism: Amgen’s Uplizna Shows Promise but Limited Immediate Impact on Valuation
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.
FiercePharma23d
With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
Uplizna was one of the key drugs acquired from the company’s $27.8 billion acquisition of Horizon Therapeutics, which was completed in October of last year. Amgen Uplizna Myasthenia Gravis ...
Investing3d
Amgen's UPLIZNA shows promise in myasthenia gravis trial
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG) ...
Amgen stock slides 5% as analysts weigh in on drug study results (update)
Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...